Express Scripts TRICARE contract removes key overhang, says Citigroup Citigroup believes the Express Scripts retaining the Department of Defense's TRICARE Pharmacy Program contract removes a key overhang on the stock and validates the company's business model. Citi reiterates a Buy rating on Express Scripts with a $92 price target.
Express Scripts CEO says Gilead relationship 'important' going forward Express Scripts (ESRX) CEO George Paz at the J.P. Morgan Healthcare Conference said his company's relationship with Gilead (GILD) is "important" going forward. Paz said his company's goal is not to exclude drugs. He continues to discuss Express Scripts's deal with AbbVie (ABBV) and the company's goal of saving clients money with regards to healthcare costs.